CDK4 and glioblastoma: Critically, 1 maintained the ability to inhibit nuclear pRb and E2F1 in patient-derived glioblastoma cells, and thus we can be confident that palbociclib was still acting on its CDK4/6 target when conjugated to MHI 148 (Fig. 3A).